Fibrocell Science Inc. (FCSC) Financial Statements (2023 and earlier)
Company Profile
| Business Address |
405 EAGLEVIEW BOULEVARD EXTON, PA 19341 |
| State of Incorp. | DE |
| Fiscal Year End | December 31 |
| Industry (SIC) | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)Annual | Quarterly
| 12/31/2018 | 12/31/2017 | 12/31/2016 | 12/31/2015 | 12/31/2014 | 12/31/2013 | |||
|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||
| Current Assets | ||||||||
| Cash, cash equivalents, and short-term investments | 14,430 | 17,417 | 17,515 | 29,268 | 37,495 | 60,033 | ||
| Cash and cash equivalents | 14,430 | 17,417 | 17,515 | 29,268 | 37,495 | 60,033 | ||
| Receivables | (12) | 4 | 28 | |||||
| Inventory, net of allowances, customer advances and progress billings | 482 | 571 | 597 | |||||
| Inventory | 482 | 571 | 597 | |||||
| Other undisclosed current assets | 105 | 485 | 513 | 1,256 | 1,278 | 1,202 | ||
| Total current assets: | 14,535 | 17,902 | 18,028 | 30,994 | 39,348 | 61,860 | ||
| Noncurrent Assets | ||||||||
| Property, plant and equipment | 1,222 | 1,470 | 1,489 | 1,582 | 1,598 | 1,701 | ||
| Intangible assets, net (including goodwill) | 4,136 | 4,687 | 5,238 | |||||
| Intangible assets, net (excluding goodwill) | 4,136 | 4,687 | 5,238 | |||||
| Other noncurrent assets | 1 | 39 | 65 | 1 | 215 | |||
| Total noncurrent assets: | 1,223 | 1,509 | 1,554 | 5,718 | 6,286 | 7,154 | ||
| TOTAL ASSETS: | 15,758 | 19,411 | 19,582 | 36,712 | 45,634 | 69,014 | ||
| LIABILITIES AND EQUITY | ||||||||
| Liabilities | ||||||||
| Current Liabilities | ||||||||
| Accounts payable and accrued liabilities | 1,922 | 2,122 | 1,991 | 2,278 | 2,799 | 3,445 | ||
| Accounts payable | 452 | 862 | 440 | 499 | 1,124 | 2,958 | ||
| Accrued liabilities | 1,470 | 1,260 | 1,551 | 1,779 | 1,675 | 487 | ||
| Deferred rent credit | 150 | ✕ | ✕ | ✕ | ✕ | ✕ | ||
| Due to related parties | 100 | 2,303 | 942 | 10,720 | ||||
| Deferred revenue and credits | ✕ | 457 | 416 | 148 | ||||
| Other undisclosed current liabilities | 54 | 1,910 | 278 | |||||
| Total current liabilities: | 2,172 | 4,425 | 2,987 | 15,365 | 3,493 | 3,593 | ||
| Noncurrent Liabilities | ||||||||
| Liabilities, other than long-term debt | 2,139 | 3,939 | 2,526 | 779 | 724 | 539 | ||
| Deferred revenue and credits | ✕ | 803 | 791 | |||||
| Deferred rent credit | 665 | ✕ | ✕ | ✕ | ✕ | ✕ | ||
| Other liabilities | 779 | 724 | 539 | |||||
| Derivative instruments and hedges, liabilities | 1,474 | 3,136 | 1,735 | |||||
| Other undisclosed noncurrent liabilities | 1,890 | 2,040 | 6,208 | 6,365 | 11,008 | 15,216 | ||
| Total noncurrent liabilities: | 4,029 | 5,979 | 8,734 | 7,144 | 11,732 | 15,755 | ||
| Total liabilities: | 6,201 | 10,404 | 11,721 | 22,509 | 15,225 | 19,348 | ||
| Stockholders' equity | ||||||||
| Stockholders' equity attributable to parent | 9,557 | 9,007 | 7,861 | 14,203 | 30,409 | 49,666 | ||
| Common stock | 10 | 26 | 44 | 44 | 41 | 40 | ||
| Additional paid in capital | 198,627 | 187,784 | 170,380 | 161,330 | 143,086 | 136,694 | ||
| Accumulated deficit | (189,080) | (178,803) | (162,563) | (147,171) | (112,718) | (87,068) | ||
| Total stockholders' equity: | 9,557 | 9,007 | 7,861 | 14,203 | 30,409 | 49,666 | ||
| TOTAL LIABILITIES AND EQUITY: | 15,758 | 19,411 | 19,582 | 36,712 | 45,634 | 69,014 | ||
Income Statement (P&L) ($ in thousands) Annual | Quarterly
| 12/31/2018 | 12/31/2017 | 12/31/2016 | 12/31/2015 | 12/31/2014 | 12/31/2013 | ||
|---|---|---|---|---|---|---|---|
| Revenues | 355 | 492 | 180 | 200 | |||
| Revenue, net | ✕ | 337 | 270 | 180 | 200 | ||
| Cost of revenue | (697) | (722) | (2,312) | (8,052) | |||
| Cost of goods and services sold | (696) | (426) | (2,312) | (8,052) | |||
| Gross profit: | (342) | (230) | (2,132) | (7,852) | |||
| Operating expenses | (12,389) | (13,261) | (22,413) | (21,855) | (28,447) | (23,236) | |
| Other undisclosed operating income (loss) | (5,720) | (3,724) | (15,322) | 625 | 585 | ||
| Operating loss: | (12,389) | (18,981) | (26,479) | (37,407) | (29,954) | (30,503) | |
| Nonoperating income (expense) (Other Nonoperating Income (Expense)) | (7) | 17 | 368 | ||||
| Interest and debt expense | (771) | (828) | (228) | 2 | |||
| Other undisclosed income (loss) from continuing operations before equity method investments, income taxes | 3,936 | (1,053) | |||||
| Loss from continuing operations before equity method investments, income taxes: | (13,160) | (19,809) | (26,714) | (37,390) | (25,650) | (31,554) | |
| Other undisclosed income from continuing operations before income taxes | 2,883 | 3,569 | 11,422 | 2,937 | |||
| Net loss attributable to parent: | (10,277) | (16,240) | (15,292) | (34,453) | (25,650) | (31,554) | |
| Preferred stock dividends and other adjustments | (336) | (264) | |||||
| Other undisclosed net loss available to common stockholders, basic | (513) | (4,099) | |||||
| Net loss available to common stockholders, basic: | (11,126) | (20,603) | (15,292) | (34,453) | (25,650) | (31,554) | |
| Dilutive securities, effect on basic earnings per share | (34) | (1,958) | 1,529 | ||||
| Other undisclosed net loss available to common stockholders, diluted | (3,058) | (2,840) | (2,267) | ||||
| Net loss available to common stockholders, diluted: | (11,126) | (20,637) | (17,250) | (35,982) | (28,490) | (33,821) | |
Comprehensive Income ($ in thousands)Annual | Quarterly
| 12/31/2018 | 12/31/2017 | 12/31/2016 | 12/31/2015 | 12/31/2014 | 12/31/2013 | ||
|---|---|---|---|---|---|---|---|
| Net loss: | (10,277) | (16,240) | (15,292) | (34,453) | (25,650) | (31,554) | |
| Comprehensive loss, net of tax, attributable to parent: | (10,277) | (16,240) | (15,292) | (34,453) | (25,650) | (31,554) | |
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.